Literature DB >> 25031504

Matrix metalloproteinases, atherosclerosis, proteinuria and kidney disease: Linkage-based approaches.

G Dimas1, F Iliadis1, D Grekas1.   

Abstract

Matrix metalloproteinases (MMPs) are important enzymes of extracellular matrix (ECM) degradation for creating the cellular environments required during development and morphogenesis. MMPs, collectively called matrixins, regulate also the biological activity of non matrix substrates such as cytokines, chemokines, receptors, growth factors and cell adhesion molecules. Enzymatic activity is regulated at multiple levels. Endogenous specific inhibitors of metalloproteinases (TIMPs) participate in controlling the local activities of MMPs in tissues. The pathological effects of MMPs and TIMPs are involved in cardiovascular disease (CVD) processes, including atherosclerosis and in a number of renal pathophysiologic alterations, both acute and chronic, linking them to acute kidney injury, glomerulosclerosis and tubulointerstitial fibrosis. This review presents an overview of the place of MMPs in atherosclerosis, proteinuria and kidney disease as a subject of considerable interest, given the differentiated and ambiguous role of MMPs in the progression of these diseases.

Entities:  

Keywords:  Matrix metalloproteinases; atherosclerosis; glomerulonephritis; glomerulosclerosis; kidney disease; proteinuria; tubulointerstitial fibrosis

Year:  2013        PMID: 25031504      PMCID: PMC4097406     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  42 in total

1.  Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease.

Authors:  Tim S Johnson; Marie Fisher; John L Haylor; Zoe Hau; N James Skill; Richard Jones; Robert Saint; Ian Coutts; Melissa E Vickers; A Meguid El Nahas; Martin Griffin
Journal:  J Am Soc Nephrol       Date:  2007-11-14       Impact factor: 10.121

2.  Transforming growth factor-beta selectively inhibits branching morphogenesis but not tubulogenesis.

Authors:  H Sakurai; S K Nigam
Journal:  Am J Physiol       Date:  1997-01

3.  Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury.

Authors:  Sunfa Cheng; Allan S Pollock; Rajeev Mahimkar; Jean L Olson; David H Lovett
Journal:  FASEB J       Date:  2006-08-04       Impact factor: 5.191

4.  Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery.

Authors:  G Pasterkamp; A H Schoneveld; D J Hijnen; D P de Kleijn; H Teepen; A C van der Wal; C Borst
Journal:  Atherosclerosis       Date:  2000-06       Impact factor: 5.162

5.  Transmural pressure induces matrix-degrading activity in porcine arteries ex vivo.

Authors:  N C Chesler; D N Ku; Z S Galis
Journal:  Am J Physiol       Date:  1999-11

Review 6.  Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.

Authors:  Zorina S Galis; Jaikirshan J Khatri
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

7.  Circulating matrix metalloproteinase-2 is an independent correlate of proteinuria in patients with chronic kidney disease.

Authors:  Makio Nagano; Kei Fukami; Sho-ichi Yamagishi; Seiji Ueda; Yusuke Kaida; Takafumi Matsumoto; Junko Yoshimura; Takuma Hazama; Yoshimi Takamiya; Takuo Kusumoto; Shojiro Gohara; Hideharu Tanaka; Hisashi Adachi; Seiya Okuda
Journal:  Am J Nephrol       Date:  2008-08-14       Impact factor: 3.754

8.  Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling.

Authors:  Kebin Hu; Chuanyue Wu; Wendy M Mars; Youhua Liu
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 9.  Human matrix metalloproteinases: characteristics and pathologic role in altering mesangial homeostasis.

Authors:  John Keeling; Guillermo A Herrera
Journal:  Microsc Res Tech       Date:  2008-05       Impact factor: 2.769

Review 10.  Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: therapeutic perspectives.

Authors:  Pierre Ronco; Christos Chatziantoniou
Journal:  Kidney Int       Date:  2008-07-23       Impact factor: 10.612

View more
  9 in total

Review 1.  The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.

Authors:  Griselda A Cabral-Pacheco; Idalia Garza-Veloz; Claudia Castruita-De la Rosa; Jesús M Ramirez-Acuña; Braulio A Perez-Romero; Jesús F Guerrero-Rodriguez; Nadia Martinez-Avila; Margarita L Martinez-Fierro
Journal:  Int J Mol Sci       Date:  2020-12-20       Impact factor: 5.923

Review 2.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in chronic kidney disease and acute kidney injury: a systematic review of the literature.

Authors:  C L Sampieri; R A Orozco-Ortega
Journal:  Hippokratia       Date:  2018 Jul-Sep       Impact factor: 0.471

3.  Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits.

Authors:  Wen Ding; Keyvan Yousefi; Stefania Goncalves; Bradley J Goldstein; Alfonso L Sabater; Amy Kloosterboer; Portia Ritter; Guerline Lambert; Armando J Mendez; Lina A Shehadeh
Journal:  JCI Insight       Date:  2018-03-22

4.  Generation of Matrix Degradation Products Using an In Vitro MMP Cleavage Assay.

Authors:  Niklas Wagner; Anna E Rapp; Sebastian Braun; Markus Ehnert; Thomas Imhof; Manuel Koch; Zsuzsa Jenei-Lanzl; Frank Zaucke; Andrea Meurer
Journal:  Int J Mol Sci       Date:  2022-06-02       Impact factor: 6.208

5.  Matrix metalloproteinase-1 and -2 as markers of mineral bone disease in chronic kidney disease patients.

Authors:  K Thisiadou; V Liakopoulos; G Dimas; G Koliakos; M Karamouzis
Journal:  Hippokratia       Date:  2017 Jan-Mar       Impact factor: 0.471

6.  Effect of silibinin on the expression of MMP2, MMP3, MMP9 and TIMP2 in kidney and lung after hepatic ischemia/reperfusion injury in an experimental rat model.

Authors:  Vasileios Kollaras; Georgia Valsami; Maria Lambropoulou; Ourania Konstandi; Nikolaos Kostomistsopoulos; Emmanouil Pikoulis; Constantinos Simopoulos; Alexandra Tsaroucha
Journal:  Acta Cir Bras       Date:  2021-11-08       Impact factor: 1.388

7.  The metabonomics study of P-selectin glycoprotein ligand-1 (PSGL-1) deficiency inhibiting the progression of atherosclerosis in LDLR-/- mice.

Authors:  Binglin Li; Xin Lu; Jia Wang; Xiaodong He; Quliang Gu; Lijing Wang; Yongxia Yang
Journal:  Int J Biol Sci       Date:  2018-01-01       Impact factor: 6.580

8.  Hypoxia inducible factor-1α mediates the profibrotic effect of albumin in renal tubular cells.

Authors:  Junping Hu; Weili Wang; Fan Zhang; Pin-Lan Li; Krishna M Boini; Fan Yi; Ningjun Li
Journal:  Sci Rep       Date:  2017-11-20       Impact factor: 4.379

9.  Upregulation of matrix metalloproteinase 9 (MMP9)/tissue inhibitor of metalloproteinase 1 (TIMP1) and MMP2/TIMP2 ratios may be involved in lipopolysaccharide-induced acute lung injury.

Authors:  Guobing Chen; Dandan Ge; Bizhen Zhu; Huixuan Shi; Qilin Ma
Journal:  J Int Med Res       Date:  2020-04       Impact factor: 1.671

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.